Fiscal year 2025 melanoma research program general program support, pre-application screening, programmatic review and vision setting
Ended Awarded Last action
- Contract number
- HT942525F0031
- Awardee
-
Leidos, Inc. UEI QLNMVC12KWY3 Part of Leidos Holdings, Inc.
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $214,391
Award facts
- Opportunity
-
- Meeting, Programmatic, and Administrative Support Services Pre-Solicitation · W81XWH22R0025 · Posted Aug 16, 2021
- Contract value 87% obligated
- $245,071.81 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$30,681 | |
| Funding Only Action | $69,462 | |
| Original award | $175,609 |
About this award
The Defense Health Agency awarded a delivery order valued at $245,071.81 to Leidos, Inc. (operating as SAIC through its Leidos Services Operating Segment) on December 8, 2024, for general program support, pre-application screening, programmatic review, and vision setting activities related to the Fiscal Year 2025 Melanoma Research Program. The contract employs a cost-plus-fixed-fee pricing structure and is scheduled for completion by July 31, 2025, with performance to be conducted in Frederick, Maryland. No set-aside designation was applied to this award, reflecting Leidos' competitive status as an established large prime contractor.
This delivery order represents task-level work under the Defense Health Agency's congressionally directed medical research initiatives, an area where Leidos maintains substantial expertise through its portfolio of medical research support contracts. As the parent company of multiple subsidiary divisions, Leidos Holdings, Inc. has demonstrated extensive experience supporting defense health research programs, including cancer research initiatives across multiple disease types. The relatively modest ceiling value of this delivery order is consistent with discrete project work issued under larger indefinite delivery vehicles that establish the framework for ongoing research program administration and support services across the Department of Defense medical research enterprise.
Quick answers
Who was awarded contract HT942525F0031?
HT942525F0031 was awarded to Leidos, Inc. by Defense Health Agency (Department of Defense) on December 8, 2024.
How much is contract HT942525F0031 worth?
The government has obligated $214,391 on HT942525F0031. Its current value, with exercised options, is $245,072.
Is contract HT942525F0031 an order under another contract?
Yes. HT942525F0031 is a delivery order under HT942523D0002, an indefinite delivery contract.
Was contract HT942525F0031 competed?
The extent of competition for HT942525F0031 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award